アイダホ州における過体重の臨床試験
アイダホ州内の拠点で、過体重に関する19件の研究が参加者を募集しています。
アイダホ州内の都市
公式研究テキスト（英語）
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Elite Clinical Trials - Blackfoot /ID# 282042, Blackfoot
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07752979A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Solaris Clinical Research, Meridian
被験者募集中第3相
8歳〜18歳 · 全性別 · 2026/09/30更新 · NCT07253285A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Family First Medical Center, Idaho Falls
- Solaris Clinical Research, Meridian
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07794579Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Grand Teton Research Group, Idaho Falls
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Grand Teton Research Group, Idaho Falls
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Family First Medical Center, Idaho Falls
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07392190Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Velocity Clinical Research - Boise, Meridian
被験者募集中第3相
45歳〜99歳 · 全性別 · 2026/09/22更新 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Medical Research Partners, Ammon
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/22更新 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Boise
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Boise
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Elite Clinical Trials, Blackfoot
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Elite Clinical Trials, Rexburg
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Meridian
被験者募集中第3相健康なボランティア歓迎
18歳〜79歳 · 全性別 · 2026/09/11更新 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/08更新 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Solaris Clinical Research, Meridian
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Solaris Clinical Research, Meridian
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/08/27更新 · NCT07575399Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Meridian
- ACCOMPLISH-1 Research Site, Rexburg
被験者募集中第3相
18歳〜79歳 · 全性別 · 2026/08/10更新 · NCT07654361Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
- Boise VA Medical Center, Boise
被験者募集中
18歳以上 · 全性別 · 2026/07/22更新 · NCT06390345ClinicalTrials.govより、2026/10/04時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。